Posted by Michael Wonder on 01 Nov 2023
CStone announces NMPA approval of sugemalimab for patients with relapsed or refractory extranodal NK/T-cell lymphoma, the first anti-PD-1/PD-L1 mAb approved for this indication
31 October 2023 - Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma indication.
CStone Pharmaceuticals today announced that the National Medical Products Administration of China has approved the anti-PD-L1 antibody sugemalimab (Cejemly) for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma.
